These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27206886)

  • 1. Can aerobic exercise alleviate flu-like symptoms following interferon beta-1a injections in patients with multiple sclerosis?
    Langeskov-Christensen M; Kjølhede T; Stenager E; Jensen HB; Dalgas U
    J Neurol Sci; 2016 Jun; 365():114-20. PubMed ID: 27206886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation.
    Matson MA; Zimmerman TR; Tuccillo D; Tang Y; Deykin A
    Curr Med Res Opin; 2011 Dec; 27(12):2271-8. PubMed ID: 21988668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
    Bertoli D; Serana F; Sottini A; Cordioli C; Maimone D; Amato MP; Centonze D; Florio C; Puma E; Capra R; Imberti L
    PLoS One; 2015; 10(8):e0135441. PubMed ID: 26285213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Kira J; Ueno Y; Harada N; Hirakata T
    Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.
    Landi D; Albanese M; Buttari F; Monteleone F; Boffa L; Rossi S; Motta C; Puma E; Centonze D
    PLoS One; 2017; 12(7):e0165415. PubMed ID: 28686675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flu-like syndrome due to interferon-beta injections does not increase anxiety, depression, and lost working days in multiple sclerosis patients during the Sars-CoV-2 pandemic.
    Mantero V; Basilico P; Balgera R; Rigamonti A; Sozzi M; Salmaggi A; Cordano C
    Clin Neurol Neurosurg; 2023 Sep; 232():107892. PubMed ID: 37454600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.
    Libertinova J; Meluzinova E; Tomek A; Horakova D; Kovarova I; Matoska V; Kumstyrova S; Zajac M; Hyncicova E; Liskova P; Houzvickova E; Martinkovic L; Bojar M; Havrdova E; Marusic P
    PLoS One; 2017; 12(1):e0169957. PubMed ID: 28081207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
    Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
    Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.
    Patti F; Zimatore GB; Brescia Morra V; Aguglia U; Bossio RB; Marziolo R; Valentino P; Chisari CG; Capacchione A; Zappia M;
    J Neurol; 2020 Jun; 267(6):1812-1823. PubMed ID: 32140867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A short 2 week dose titration regimen reduces the severity of flu-like symptoms with initial interferon gamma-1b treatment.
    Devane JG; Martin ML; Matson MA
    Curr Med Res Opin; 2014 Jun; 30(6):1179-87. PubMed ID: 24576196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon beta-1a (Plegridy) Italian real-world experience: a Delphi analysis of injection-site reaction and flu-like symptom management.
    Cordioli C; Callari G; Fantozzi R; Caruso F; Martucci G; Mascara S; Zipoli V
    Neurol Sci; 2021 Apr; 42(4):1515-1521. PubMed ID: 33439393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties.
    Golan D; Halhal B; Glass-Marmor L; Staun-Ram E; Rozenberg O; Lavi I; Dishon S; Barak M; Ish-Shalom S; Miller A
    BMC Neurol; 2013 Jun; 13():60. PubMed ID: 23767916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
    Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of systemic sarcoidosis and xanthoma planum during multiple sclerosis treatment with interferon-beta 1a: Case Report.
    Viana de Andrade AC; Brito ÉA; Harris OM; Viana de Andrade AP; Leite MF; Pithon MM
    Int J Dermatol; 2015; 54(5):e140-5. PubMed ID: 25208461
    [No Abstract]   [Full Text] [Related]  

  • 15. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study.
    Tenembaum SN; Banwell B; Pohl D; Krupp LB; Boyko A; Meinel M; Lehr L; Rocak S; Cantogno EV; Moraga MS; Ghezzi A;
    J Child Neurol; 2013 Jul; 28(7):849-56. PubMed ID: 23666046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis.
    Buttari F; Zagaglia S; Marciano L; Albanese M; Landi D; Nicoletti CG; Mercuri NB; Silvestrini M; Provinciali L; Marfia GA; Mori F; Centonze D
    J Neuroimmunol; 2017 Apr; 305():172-174. PubMed ID: 28284340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerobic capacity in persons with multiple sclerosis: a systematic review and meta-analysis.
    Langeskov-Christensen M; Heine M; Kwakkel G; Dalgas U
    Sports Med; 2015 Jun; 45(6):905-23. PubMed ID: 25739555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.
    Mahe J; Meurette A; Moreau A; Vercel C; Jolliet P
    Drug Des Devel Ther; 2013; 7():723-8. PubMed ID: 23950639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
    Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon β associated nephropathy in a Multiple Sclerosis patient: A case and review.
    Ozturk M; Basoglu F; Yilmaz M; Ozagari AA; Baybas S
    Mult Scler Relat Disord; 2016 Sep; 9():50-3. PubMed ID: 27645343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.